Ticker LaunchReverse merger · Completed · FBRX
Forte Biosciences, Inc.
Reverse merger with Tocagen Inc.
Forte Biosciences, Inc. merged into Tocagen Inc., a clinical-stage biopharmaceutical company, in a reverse merger that takes the private company public. The deal was announced on Feb 19, 2020 and closed on Jun 15, 2020. The combined company trades as Forte Biosciences, Inc. (FBRX) on Nasdaq.
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company formed when private Forte Biosciences merged into Tocagen, and it operates under the Forte name on Nasdaq.
- Status
- Completed
- Private company
- Forte Biosciences, Inc.
- Public company
- Tocagen Inc.
- Public company business before
- clinical-stage biopharmaceutical company
- Announced
- Feb 19, 2020
- Closed
- Jun 15, 2020
- Combined company
- Forte Biosciences, Inc. (FBRX)
- Exchange
- Nasdaq
- Sector
- Biotech & pharma
More on this deal for subscribers
- Ownership split between private and public holders
- Reverse stock split
- Analyst notes from the filings
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Closing 8-K Jun 15, 2020
- Closing press release / exhibit
- All filings on EDGAR CIK 1419041
Other completed reverse mergers
- Compass Therapeutics LLCinto Olivia Ventures, Inc. · Jun 17, 2020
- Blockgration Global Corp.into Zoompass Holdings, Inc. · May 31, 2020
- AYRO, Inc. (AYRO Operating Company)into DropCar, Inc. · May 28, 2020
- Chondrial Therapeutics, Inc.into Zafgen, Inc. · May 28, 2020
- GSL Healthcare, Inc.into Agentix Corp. · May 28, 2020
- Histogen Inc.into Conatus Pharmaceuticals Inc. · May 26, 2020